Angiogenesis inhibitors in the treatment of epithelial ovarian cancer

Current Treatment Options in Oncology

Volumn 14, Issue 1, 2013, Pages 22-33

  Han, Ernest S ^a   Wakabayashi, Mark ^a   Leong, Lucille ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Ovarian cancer; VEGF

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEMCITABINE; PACLITAXEL; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; THALIDOMIDE; TOPOTECAN; TREBANANIB; VATALANIB; VOLOCIXIMAB;

ADVANCED CANCER; ANEMIA; ANTIANGIOGENIC THERAPY; ANUS FISSURE; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CYTOREDUCTIVE SURGERY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DYSPHONIA; DYSPNEA; FATIGUE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOKALEMIA; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; LIVER FUNCTION TEST; LOW DRUG DOSE; METABOLIC DISORDER; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; OVERALL SURVIVAL; PAIN; PERITONEUM CANCER; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECURRENT CANCER; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; UTERINE TUBE TUMOR; WEIGHT REDUCTION;

EID: 84873714403     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-012-0220-6     Document Type: Article

References (46)

1. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8(8):579-91. doi: 10.1038/nrc2403.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.
3. Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. The Lancet Oncol. 2010;11(12):1172-83. doi: 10.1016/S1470-2045(10)70232-1.
4. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi: 10.3322/caac.20107.
5. Disaia PJ, Creasman WT. Clinical gynecologic oncology. 7th ed. Saint Louis: Mosby-Year Book; 2007.
6. Monk BJ, Choi DC, Pugmire G, Burger RA. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol. 2005;96(3):902-5. doi: 10.1016/j.ygyno.2004.12.001.
7. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(33):5165-71. doi: 10.1200/JCO.2007.11.5345.
8. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25(33):5180-6. doi: 10.1200/JCO.2007.12.0782.
9. Chura JC, Van Iseghem K, Downs Jr LS, Carson LF, Judson PL. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol. 2007;107(2):326-30. doi: 10.1016/j.ygyno.2007.07.017.
10. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008;26(1):76-82. doi: 10.1200/JCO.2007.12.1939.
11. Sanchez-Munoz A, Mendiola C, Perez-Ruiz E, Rodriguez-Sanchez CA, Jurado JM, Alonso-Carrion L, et al. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Oncology. 2010;79(1-2):98-104. doi: 10.1159/000320602.
12. Sanchez-Munoz A, Jurado JM, Perez-Ruiz E, Alba E. Second complete remission induced by cyclophosphamide plus bevacizumab in two patients with heavily pre-treated ovarian cancer. Clin Transl Oncol. 2009;11(5):329-31.
13. Hurt JD, Richardson DL, Seamon LG, Fowler JF, Copeland LJ, Cohn DE, et al. Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. Gynecol Oncol. 2009;115(3):396-400. doi: 10.1016/j.ygyno.2009.08.032.
14. Richardson DL, Backes FJ, Seamon LG, Zanagnolo V, O'Malley DM, Cohn DE, et al. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol. 2008;111(3):461-6. doi: 10.1016/j.ygyno.2008.08.011.
15. McGonigle KF, Muntz HG, Vuky J, Paley PJ, Veljovich DS, Greer BE, et al. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer. 2011;117(16):3731-40. doi: 10.1002/cncr.25967.
16. Kudoh K, Takano M, Kouta H, Kikuchi R, Kita T, Miyamoto M, et al. Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers. Gynecol Oncol. 2011;122(2):233-7. doi: 10.1016/j.ygyno.2011.04.046.
17. del Carmen MG, Micha J, Small L, Street DG, Londhe A, McGowan T. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol. 2012;126(3):369-74. doi: 10.1016/j.ygyno.2012.05.028.
18. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28(20):3323-9. doi: 10.1200/JCO.2009.25. 7519.
19. Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2008;110(1):49-55. doi: 10.1016/j.ygyno.2008.02.009.
20. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol. 2008;26(22):3709-14. doi: 10.1200/JCO.2007.10.8332.
21. Kohn EC, Lee J, Annunziata CM, Minasian LM, Zujewski J, Prindiville SA et al. A phase II study of intermittent sorafenib with bevacizumab in bevacizumab-naive epithelial ovarian cancer (EOC) patients. J Clin Oncol. 2011;29(suppl. abstr 5019).
22. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039-45. doi: 10.1200/JCO.2012.42.0505. This is the first positive III study of an anti-angiogenic biologic therapy in the recurrent disease setting.
23. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G et al. AURELIA: A randomized phase III trial evaluating bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer. J Clin Oncol. 2012;30:suppl:abstr LBA5002.
24. Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010;28(1):154-9. doi: 10.1200/JCO.2009.22.7900.
25. Micha JP, Goldstein BH, Rettenmaier MA, Genesen M, Graham C, Bader K, et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer. 2007;17(4):771-6. doi: 10.1111/j.1525-1438. 2007.00886.x.
26. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473-83. doi: 10.1056/NEJMoa1104390. This phase III study reports on antiangiogenic biologic therapy in the front-line setting (also see Perren et al).
27. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484-96. doi: 10.1056/NEJMoa1103799. This phase III study reports on antiangiogenic biologic therapy in the front-line setting (also see Burger et al).
28. Bookman MA. First-line chemotherapy in epithelial ovarian cancer. Clin Obstet Gynecol. 2012;55(1):96-113. doi: 10.1097/GRF.0b013e31824b45da.
29. Tew WP, Colombo N, Ray-Coquard I, Oza A, del Campo J, Scambia G et al. VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study. J Clin Oncol. 2007;Part I. Vol 25, No. 18S(June 20 Supplement).
30. Colombo N, Mangili G, Mammoliti S, Kalling M, Tholander B, Sternas L, et al. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecol Oncol. 2012;125(1):42-7. doi: 10.1016/j.ygyno.2011.11.021.
31. Gotlieb WH, Amant F, Advani S, Goswami C, Hirte H, Provencher D, et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. The Lancet Oncol. 2012;13(2):154-62. doi: 10.1016/S1470-2045(11)70338-2.
32. Coleman RL, Duska LR, Ramirez PT, Heymach JV, Kamat AA, Modesitt SC, et al. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. The Lancet Oncol. 2011;12(12):1109-17. doi: 10.1016/S1470-2045(11)70244-3.
33. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009;27(33):5601-6. doi: 10.1200/JCO.2009.23. 2777.
34. Hirte HW, Vidal L, Fleming GF, Sugimoto AK, Morgan RJ, Biagi JJ et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial. J Clin Oncol. 2008 26((May 20 suppl; abstr 5521)).
35. Raja FA, Griffin CL, Qian W, Hirte H, Parmar MK, Swart AM, et al. Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer. Br J Cancer. 2011;105(7):884-9. doi: 10.1038/bjc.2011.334.
36. Matei D, Sill MW, Lankes HA, DeGeest K, Bristow RE, Mutch D, et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol. 2011;29(1):69-75. doi: 10.1200/JCO.2009.26.7856.
37. Welch SA, Hirte HW, Elit L, Schilder RJ, Wang L, Macalpine K, et al. Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium. Int J Gynecol Cancer. 2010;20(5):787-93. doi: 10.1111/IGC.0b013e3181e273a8.
38. Matei D, Ramasubbaiah R, Schilder J, Perkins S, Whalen C, Breen T et al. A phase I/II study of topotecan and sorafenib in recurrent, platinum-resistant ovarian cancer: HOG GYN-111. J Clin Oncol. 2010;28(15s):suppl; abstr 5108.
39. Biagi JJ, Oza AM, Chalchal HI, Grimshaw R, Ellard SL, Lee U, et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol. 2011;22(2):335-40. doi: 10.1093/annonc/mdq357.
40. Friedlander M, Hancock KC, Benigno B, Rischin D, Messing M, Stringer CA et al. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II study. J Clin Oncol. 2007;25, No. 18S(June 20 Supplement):2007:5561.
41. Eichbaum M, Mayer C, Eickhoff R, Bischofs E, Gebauer G, Fehm T, et al. The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer. BMC Cancer. 2011;11:453. doi: 10.1186/1471-2407-11-453.
42. Juretzka MM, Aghajanian C, Hensley ML, Tew WP, Spriggs D, Konner J et al. Phase I trial of PTK787/ZK222584 (PTK/ZK) in combination with carboplatin (C) and paclitaxel (T) in platinum-sensitive recurrent epithelial ovarian (EOC), fallopian tube (FT), or primary peritoneal (PPC) cancers. J Clin Oncol. 2007 25 - Part I(June 20 No. 18S):Supplement 5564.
43. Delmonte A, Del Conte G, Sessa C, Perotti A, Fasolo A, Williams E et al. Results from a phase 1/2 study of volociximab in combination with liposomal doxorubicin in relapsed advanced epithelial ovarian and primary peritoneal carcinoma. J Clin Oncol. 2008;26(May 20 suppl; abstr 16527).
44. Karlan BY, Oza AM, Richardson GE, Provencher DM, Hansen VL, Buck M, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol. 2012;30(4):362-71. doi: 10.1200/JCO.2010.34.3178.
45. Downs Jr LS, Judson PL, Argenta PA, Ghebre R, Geller MA, Bliss RL, et al. A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer. 2008;112(2):331-9. doi: 10.1002/cncr.23164.
46. Hurteau JA, Brady MF, Darcy KM, McGuire WP, Edmonds P, Pearl ML, et al. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol. 2010;119(3):444-50. doi: 10.1016/j.ygyno.2010.08.002.